Tumor lysis syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
==Prevention== | ==Prevention== | ||
Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, should receive the following: | Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, patients should receive the following: | ||
*[[Allopurinol]] | *[[Allopurinol]] | ||
*[[Rasburicase]] (uricase) is an alternative to allopurinol and is reserved for patients who are at high-risk for developing tumor lysis syndrome | *[[Rasburicase]] (uricase) is an alternative to allopurinol and is reserved for patients who are at high-risk for developing tumor lysis syndrome | ||
Revision as of 15:19, 30 September 2015
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome primary prevention |
|
Risk calculators and risk factors for Tumor lysis syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Effective measures for the primary prevention of tumor lysis syndrome include allopurinol, rasburicase, and intravenous hydration.
Prevention
Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, patients should receive the following:
- Allopurinol
- Rasburicase (uricase) is an alternative to allopurinol and is reserved for patients who are at high-risk for developing tumor lysis syndrome
- Adequate intravenous hydration to maintain a high urine output (> 2.5 L/day)
- Alkalinization of the urine with acetazolamide or sodium bicarbonate is controversial